Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: Report on 15 cases and literature review

Critical Care

Volumn 17, Issue 2, 2013, Pages

  Repessé, Xavier ^a,b   Au, Siu Ming ^a,b   Bréchot, Nicolas ^a,b   Trouillet, Jean Louis ^a,b   Leprince, Pascal ^a,b   Chastre, Jean ^a,b   Combes, Alain ^a,b   Luyt, Charles Edouard ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ARTIFICIAL EMBOLISM; ARTIFICIAL VENTILATION; BLEEDING; BRAIN DEATH; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DYING; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INTENSIVE CARE UNIT; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT DURATION; UTERUS BLEEDING; CASE REPORT; HEMORRHAGE; MIDDLE AGED; PROCEDURES;

ADULT; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84875350417     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12581     Document Type: Article

References (35)

1. Combes A, Leprince P, Luyt CE, Bonnet N, Trouillet JL, Leger P, Pavie A, Chastre J. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 2008, 36:1404-1411. 10.1097/CCM.0b013e31816f7cf7, 18434909.
2. Gaffney AM, Wildhirt SM, Griffin MJ, Annich GM, Radomski MW. Extracorporeal life support. BMJ 2010, 341:c5317. 10.1136/bmj.c5317, 21045023.
3. Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008, 17(Suppl 4):S41-S47.
4. Brogan TV, Thiagarajan RR, Rycus PT, Bartlett RH, Bratton SL. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med 2009, 35:2105-2114. 10.1007/s00134-009-1661-7, 19768656.
5. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009, 13:154-175. 10.1177/1089253209347384, 19767408.
6. Heilmann C, Geisen U, Beyersdorf F, Nakamura L, Benk C, Trummer G, Berchtold-Herz M, Schlensak C, Zieger B. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012, 38:62-68. 10.1007/s00134-011-2370-6, 21965100.
7. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999, 82:531-539.
8. Mitra B, Phillips L, Cameron PA, Billah B, Reid C. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care 2010, 38:671-677.
9. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007, CD005011.
10. Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003, 98:1513-1515. 10.1097/00000542-200306000-00034, 12766668.
11. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001, 71:402-405. 10.1097/00007890-200102150-00011, 11233901.
12. Scher C, Narine V, Chien D. Recombinant factor VIIa in trauma patients without coagulation disorders. Anesthesiol Clin 2010, 28:681-690. 10.1016/j.anclin.2010.08.011, 21074745.
13. Stein DM, Dutton RP, O'Connor J, Alexander M, Scalea TM. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma 2005, 59:609-615.
14. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011, 154:529-540. 10.7326/0003-4819-154-8-201104190-00004, 21502651.
15. Brose S, Sirbu H, Engel M, Kuhlen R, Autschbach R. Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation. Thorac Cardiovasc Surg 2005, 53:389-390.
16. Veldman A, Neuhaeuser C, Akintuerk H, Thul J, Gehron J, Schranz D, Michel-Behnke I. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 2007, 17:1176-1181. 10.1111/j.1460-9592.2007.02328.x, 17986036.
17. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002, 124:852-854. 10.1067/mtc.2002.126038, 12324751.
18. Syburra T, Lachat M, Genoni M, Wilhelm MJ. Fatal outcome of recombinant factor VIIa in heart transplantation with extracorporeal membrane oxygenation. Ann Thorac Surg 2010, 89:1643-1645. 10.1016/j.athoracsur.2009.09.039, 20417801.
19. Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JC, Mercat A, Brochard L, Brun-Buisson C, Chastre J,. REVA Study Group Long-term outcomes of pandemic 2009 influenza A (H1N1)-associated severe acute respiratory distress syndrome. Chest 2012, 142:583-592. 10.1378/chest.11-2196, 22948576, REVA Study Group.
20. Mirabel M, Luyt CE, Leprince P, Trouillet JL, Leger P, Pavie A, Chastre J, Combes A. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med 2011, 39:1029-1035. 10.1097/CCM.0b013e31820ead45, 21336134.
21. Schmidt M, Bréchot N, Hariri S, Guiguet M, Luyt CE, Makri R, Leprince P, Trouillet JL, Pavie A, Chastre J, Combes A. Nosocomial infections in adult cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation. Clin Infect Dis 2012, 55:1633-1641. 10.1093/cid/cis783, 22990851.
22. Agarwal HS, Bennett JE, Churchwell KB, Christian KG, Drinkwater DC, He Y, Taylor MB. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007, 84:161-168. 10.1016/j.athoracsur.2007.02.051, 17588404.
23. Chalwin RP, Tiruvoipati R, Peek GJ. Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 2008, 34:685-686. 10.1016/j.ejcts.2008.05.022, 18579402.
24. Dominguez TE, Mitchell M, Friess SH, Huh JW, Manno CS, Ravishankar C, Gaynor JW, Tabbutt S. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2005, 6:348-351. 10.1097/01.PCC.0000161623.51275.0F, 15857537.
25. Dunne B, Xiao P, Andrews D. Successful use of factor VIIa to control life-threatening post-operative haemorrhage in a patient on extra-corporeal membrane oxygenation. Heart Lung Circ 2012, 21:229-230. 10.1016/j.hlc.2011.09.007, 22036715.
26. Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Paediatr Anaesth 2009, 19:364-370. 10.1111/j.1460-9592.2008.02905.x, 19143947.
27. Niebler RA, Punzalan RC, Marchan M, Lankiewicz MW. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2010, 11:98-102. 10.1097/PCC.0b013e3181b0620b, 19561557.
28. Schneider AG, Perez MH, Tozzi P, Voirol P, Schoettker P, Angelillo-Scherrer A, Cotting J, Von Segesser L, Eggimann P. Recombinant factor VIIa for intractable life-threatening bleeding in patients with circulatory assist devices. Intensive Care Med 2010, 36:1620-1621. 10.1007/s00134-010-1937-y, 20521024.
29. Velik-Salchner C, Sergi C, Fries D, Moser P, Streif W, Kolbitsch C. Use of recombinant factor VIIa (Novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth Analg 2005, 101:924.
30. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005, 6:473-476. 10.1097/01.PCC.0000162449.55887.B9, 15982438.
31. Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA 2009, 106:19274-19279. 10.1073/pnas.0909755106, 2780749, 19880749.
32. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011, 154:516-522. 10.7326/0003-4819-154-8-201104190-00002, 21502649.
33. Franchini M, Veneri D, Lippi G. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coagul Fibrinol 2006, 17:615-619.
34. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011, 117:6777-6785. 10.1182/blood-2010-11-297580, 21540459.
35. Basso IN, Keeling D. Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinol 2004, 15:503-504.